Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA)

Nika Schuermans1,2†, Dimitri Hemelsoet3†, Wim Teryn4, Sanne Steyaert5, Rudy Van Coster6, Paul J. Coucke1,2, Wouter Steyaert7, Bert Callewaert1,2, Elke Bogaert1,2, Patrick Verloo6, Arnaud V. Vanlander6, Elke Debackere1,2, Jody Ghijsels1,2, Pontus LeBlanc1,2, Hannah Verdin1,2, Leslie Naesens8,9, Filomeen Haerynck8, Steven Callens9, Bart Dermaut1,2†, Bruce Poppe1,2† for UD-PrOZA

Abstract

Background: In order to facilitate the diagnostic process for adult patients suffering from a rare disease, the Undiagnosed Disease Program (UD-PrOZA) was founded in 2015 at the Ghent University Hospital in Belgium. In this study we report the five-year results of our multidisciplinary approach in rare disease diagnostics.

Methods: Patients referred by a healthcare provider, in which an underlying rare disease is likely, qualify for a UD-PrOZA evaluation. UD-PrOZA uses a multidisciplinary clinical approach combined with state-of-the-art genomic technologies in close collaboration with research facilities to diagnose patients.

Results: Between 2015 and 2020, 692 patients (94% adults) were referred of which 329 (48%) were accepted for evaluation. In 18% (60 of 329) of the cases a definite diagnosis was made. 88% (53 of 60) of the established diagnoses had a genetic origin. 65% (39 of 60) of the genetic diagnoses were made through whole exome sequencing (WES). The mean time interval between symptom-onset and diagnosis was 19 years. Key observations included novel genotype–phenotype correlations, new variants in known disease genes and the identification of three new disease genes. In 13% (7 of 53), identifying the molecular cause was associated with therapeutic recommendations and in 88% (53 of 177), gene specific genetic counseling was made possible. Actionable secondary findings were reported in 7% (12 of 177) of the patients in which WES was performed.

Conclusion: UD-PrOZA offers an innovative interdisciplinary platform to diagnose rare diseases in adults with previously unexplained medical problems and to facilitate translational research.

Keywords: Rare diseases, UD-PrOZA, Diagnostic odyssey, Whole exome sequencing, Diagnostic yield, MAP3K7, SGO1, SNORD118, IRF2BPL, PLAAT3, ACMSD

Background

In Europe rare diseases are defined as diseases with a prevalence of less than 5/10,000, in the United States diseases that affect less than 200,000 Americans are classified as rare [1–3]. To date, over 6000 rare diseases have been identified, affecting 3.5—5.9% of the worldwide population [4]. Rare diseases are often chronic and disabling and therefore represent a major public health challenge.
The majority of rare diseases (80%) have a genetic origin [1]. The rarity complicates research in this field due to recruitment issues on the one hand, and a lack of interest of investors and pharmaceutical companies on the other [5]. In 2010 the Directorate-General for Research and Innovation of the European Commission (EC), together with the US National Institutes of Health (NIH), founded the International Rare Disease Research Consortium (IRDiRC), intended to establish a global partnership to advance rare disease research [3]. International collaboration via secure data exchange platforms, e.g. Matchmaker Exchange [6, 7], together with the advent of next-generation sequencing (NGS) technology, enabling hypothesis-free approaches, have boosted the discovery of new disease genes over the past decade [8]. The diagnostic yield for whole exome sequencing (WES) and whole genome sequencing (WGS) in the literature ranges from 3 to 70% depending on the patient cohort analyzed [9]. An early implementation of WES in pediatric cohorts presenting with neurodevelopmental disorders has proven to be cost-efficient [10]. Moreover, NGS enables the identification of more than one disease-causing variant in one patient. In a large NGS cohort, approximately 5% of the patients were diagnosed based on pathogenic variants in two or more disease loci [2]. Despite this tremendous progress in rare disease knowledge, 50% of the patients with the suspicion of a rare genetic disease remain undiagnosed [11]. Techniques to address this missing heritability (WGS, epigenomics, transcriptomics) are becoming increasingly incorporated in diagnostics, putting emphasis on the importance of regulatory and non-coding sequences [2]. To elaborate on potential novel disease genes or rare sequencing variants of unknown clinical significance (VUS), in vivo and in vitro functional assays are indispensable [7, 8, 12, 13]. As such, boundaries between diagnostics and research are becoming increasingly blurred, and close collaboration between clinicians, geneticists, molecular biologists, model organism experts and bioinformaticians is necessary. The identification of the molecular cause of a rare disease not only has important psychological consequences for patients and their families, in some cases (approximately 20%) it can lead to changes in recommendations regarding therapy [14]. Pinpointing the underlying genetic cause of a rare disease or identifying a genetic vulnerability predisposing for more frequent disorders, are prerequisites ultimately paving the way for precision medicine. Even in cases where the identification of the molecular cause has no therapeutic implications, it provides important prognostic information and enables correct genetic counseling regarding recurrence risk, predictive testing in relatives, prenatal genetic testing and pre-implantation genetic diagnosis.

Rare disease initiatives all over the world are being established and have reported impressive diagnostic yields ranging from 35–67%, including predominantly pediatric patients with undiagnosed diseases [14–19]. Data on the efficiency of comparable programs in adult patient cohorts with unsolved medical problems are lacking.

In 2015, UD-PrOZA (Program for Undiagnosed Rare Diseases or ‘Programma voor Ongediagnosticeerde Zeldzame Aandoeningen’ in Dutch) was founded at the Ghent University Hospital. Four clinicians with different areas of expertise (genetics, neurology, infectiology/immunology, nephrology) created a multidisciplinary platform to deal with diagnostically challenging cases. Shortly after, the team was reinforced by a neuro-geneticist, bioinformatician, molecular geneticist, clinical genetics trainee and a pediatrician. The primary aim of the initiative is to facilitate the diagnostic process for adult patients suffering from an undiagnosed rare disease. In 2019, UD-PrOZA became part of the Undiagnosed Disease Network International (UDNI) and it got involved in ‘Solve-RD,’ a rare disease research project funded by the EC for five years (2018–2022).

**Methods**

In this study we report the establishment and the five-year diagnostic results of our multidisciplinary platform aiming to diagnose predominantly adult patients with rare diseases, UD-PrOZA. We evaluated all referred cases between July 2015, until June 2020. Patient characteristics, main clinical features, type of referral and diagnostic yield were determined. Data were gathered from a UD-PrOZA registry. Statistical analysis was performed in SPSS 26 (IBM Corp. Released 2019. IBM SPSS for Windows, Version 26.0. Armonk, NY: IBM Corp). The study was approved by the Ethics Committee of the University Hospital of Ghent (EC: 2019/1430). Written informed consents were obtained from all patients included in this study in which exome sequencing and/or multi-omics analyses were performed.

Patients with unsolved medical problems can be referred to UD-PrOZA by a healthcare provider. The medical records of all applicants are evaluated by a multidisciplinary team that decides on the likelihood of an underlying rare disease. Prior evaluation in routine diagnostic setting and the presence of at least one objectifiable disease sign are prerequisites for acceptance. If a rare disease is suspected, patients are invited for further evaluation after which in most cases, genetic testing is initiated. UD-PrOZA uses multi-omics strategies, model organisms (*Drosophila* and zebrafish facilities) and data sharing platforms to elaborate on novel disease variants.
or potential novel disease genes. An overview of the UD-PrOZA workflow is provided in figure S1.

**Results**

**Study population**

From July 2015, through June 2020, a total of 692 patients were referred to UD-PrOZA (Figure S2A). The patient characteristics are summarized in Table 1. 59% of the referrals were female, 94% were 18 years of age or older. The mean age of the patients was 42 ± 16 years. 46% of the cases were referred by their general practitioner, 37% were referred by a specialist working at the Ghent University Hospital. Neurological involvement was reported in 42% of the applicants. In respectively 22% and 18% of the patients, the symptoms were related to autoimmunity/immunology and the musculoskeletal system (Figure S2B). Out of 692 referrals, 329 patients (48%) were accepted for further UD-PrOZA evaluation and follow-up. Only patients in which routine diagnostics have failed to render a diagnosis and patients presenting with at least one objectifiable disease sign were eligible for acceptance. The likelihood of acceptance depended significantly on the nature of the presenting symptoms and the referring physician. Patients with multiple objectifiable disease signs or symptoms were 14 times more likely to be accepted (OR 14.1; 95% CI 9.5–21.0, p < 0.0001). Patients referred by a specialist were 8 times more likely to be accepted compared to patients referred by their general practitioner (OR 8.5; 95% CI 5.9–12.2, p < 0.0001). In seven patients a clinical diagnosis was made after a multidisciplinary consultation (Additional file 1: Figure S2E, Table S1, Table 2). In 237 out of 329 accepted patients (72%) genetic testing was initiated. The remaining 85 patients were referred to another trajectory since the clinical presentation in these cases was not compatible with an underlying rare disease. Within the group of patients in which we requested genetic testing, 59% (139 out of 237) underwent previous genetic testing consisting of targeted genetic tests (89%) and WES-based testing (26%). In 53 patients a definite molecular cause was identified after genetic testing, in 30 patients a potential causal variant was found (functional or segregation data are required for further classification). This results in a total diagnostic yield of 18% in patients with completed workup. Within the group of patients in which genetic testing was initiated, 22% received a definite molecular diagnosis. Remarkably, all diagnosed patients initially presented with objectifiable disease signs. Secondary findings were reported in 7% of the patients in

| Table 1 | Patient information of all referrals, of the accepted referrals and of the patients that have been diagnosed by UD-PrOZA |
|---------|------------------------------------------------------------------------------------------------------------------|
|         | All referrals (n = 692) | Accepted referrals (n = 329) | Diagnosed patients (n = 60) |
| Mean age (years ± SD) | 42 ± 16 | 40.5 ± 16 | 39 ± 14 |
| Sex (%) | | | |
| Male | 277 (41) | 144 (44) | 30 (50) |
| Female | 400 (59) | 183 (56) | 30 (50) |
| Referred by (%) | | | |
| General practitioner | 292 (46) | 67 (21) | 7 (12) |
| Specialist | 348 (54) | 249 (79) | 51 (88) |
| Complaint (%) | | | |
| Objectifiable | 386 (60) | 285 (87) | 60 (100) |
| Not objectifiable | 259 (40) | 44 (13) | 0 (0) |
| Primary symptoms (%) | | | |
| Neurologic | 270 (42) | 177 (54) | 35 (58) |
| Immunologic/infectious | 133 (21) | 63 (19) | 8 (14) |
| Musculoskeletal | 107 (17) | 20 (6) | 2 (3) |
| Rheumatologic | 25 (4) | 15 (5) | 0 (0) |
| Cardiac/vascular | 19 (3) | 13 (4) | 2 (3) |
| Gastrointestinal | 18 (3) | 5 (2) | 1 (2) |
| Other | 74 (11) | 36 (11) | 12 (20) |

| Table 2 | Overview of accepted cases, diagnosed cases and cases with secondary findings; absolute and relative (%) |
|---------|-------------------------------------------------------------------------------------------------------|
| Accepted referrals | 329/692 (48) |
| Initiation of genetic testing | 237/329 (72) |
| Total diagnostic rate | 60/329 (18) |
| Clinical review/testing | 7/60 (12) |
| Targeted genetic testing | 9/60 (15) |
| CNV sequencing | 4/60 (7) |
| WES | 39/60 (65) |
| Mitochondrial DNA resequencing | 1/60 (2) |
| Potential diagnosis (VUS) | 30/329 (9) |
| Secondary findings | 12/177 (7) |
which WES was performed (Table 2, Additional file 1: Table S2).

52 genetic diagnoses after a diagnostic odyssey of 19 year on average

88% (53/60) of the established diagnoses had a genetic origin. In Table S3 an overview of all genetic diagnoses is provided. Though all patients were adults at the time of diagnosis, some patients presented the first symptoms at an early age, emphasizing the challenging diagnostics in the field of rare diseases. Strikingly, more than half of the diagnosed patients (56%) had a negative family history: in 19% (10/53) a de novo pathogenic variant was found associated with an autosomal dominant disorder, 26% (14/53) were diagnosed with an autosomal recessive disorder, 6% (3/53) were diagnosed with an X-linked recessive disorder, 2% (1/53) a pathogenic mosaic variant was identified and in 2% (1/53) a pathogenic mitochondrial DNA (mtDNA) variant in 60% heteroplasmy was found (Figure S2C, Table S3). In the other half of the patients (44%), a positive family history was seen: 25% (13/53) inherited the pathogenic variant from an affected parent, in 17% (9/53) no parental segregation analysis was performed but the family history was positive making inheritance highly likely (Additional file 1: Table S3). Consanguinity was reported in 11 cases. In 27% (3/11) homozygous pathogenic variants were detected (Additional file 1: Table S3). In total, 63 disease causing variants were detected, 27 of which (43%) have never been reported in Clinvar or in the literature to our knowledge. All variants were classified as (likely) pathogenic based on the ACMG classification criteria [20] provided in Table S3. Causal variants comprised missense variants (46%), frameshift variants (14%), nonsense variants (11%), non-coding variants (11%), larger insertion-deletion variants (10%), splice site variants (6%) and mitochondrial DNA variants (2%) (Additional file 1: Figure S2D, Table S3). The majority of the genetic diagnoses were established after WES (65%), followed by targeted genetic testing (15%) and CNV sequencing (7%) (Table 2, Additional file 1: Figure S2E). Of the cases that were diagnosed through WES, 79% were analyzed as singleton, whereas 21% were analyzed as duo or trio with affected and/or unaffected family members (Additional file 2: Table S3). For the patients with a confirmed molecular diagnosis, the time interval between symptom-onset and the moment of diagnosis was estimated at an average of 19 years, ranging from 1 to 52 years (Additional file 2: Table S3). Interestingly, three patients were molecularly diagnosed with more than one rare disease. Our diagnostic strategy had a major impact on the patient level by ending the diagnostic quest and by providing therapeutic options in some cases, but also on a scientific level, including expansion of the phenotypic spectrum and the discovery of three new monogenic diseases.

Patients diagnosed with multiple rare diseases

In three patients (Additional file 2: Table S3: ID 14, 19, 26) we identified pathogenic variants in more than one disease gene.

Patient 19, a man with a history of liposarcoma, prostate carcinoma and multiple neurofibromas was referred to UD-PrOZA because of rapidly progressive intracerebral white matter lesions resulting in a state of stupor and eventually coma. Biopsy of brain tissue was indicative of a low-grade glioma. WES revealed heterozygous likely pathogenic missense variants in NF1 (p.Leu2323Pro) (Neurofibromatosis type 1, MIM: 162200) and in TP53 (p.Arg282Gln) (Li-Fraumeni syndrome, MIM: 151623) (Additional file 2: Table S3). The NF1 variant was presumably inherited from his mother, who was also diagnosed with neurofibromas. No segregation analysis in the parents could be performed. Pathogenic variants in both NF1 and TP53 have been associated with malignant CNS tumors.

Patient 14 presented with polycystic kidney disease and progressive leukoencephalopathy. Prior targeted genetic testing detected a pathogenic variant in PKD1 (p.Tyr1159Ter) (Polycystic kidney disease 1, MIM: 173900). WES identified a missense variant in COL4A1 (p.Gly382Ser) (Microangiopathy and leukoencephalopathy, MIM: 618564) with pathogenic in silico predictions. The variant segregated with the disease in the family and was therefore classified as likely pathogenic.

In patient 26, a female presenting with polycystic kidney disease and noncompaction cardiomyopathy, WES revealed pathogenic variants in PKD1 (p.Cys3081Arg) (Polycystic kidney disease 1, MIM: 173900) and TTN (p.Trp16598Ter) (Cardiomyopathy, dilated, 1G, MIM: 604145).

Diagnoses with implications for treatment

In 7 cases (Additional file 2: Table S3: ID 4, 6, 9, 10, 11, 23, 51) (13%), identifying the underlying genetic cause had immediate consequences for the treatment or management.

Two independent male patients (patient 4 (Fig. 11–L), 11) presenting with intellectual disability, epilepsy and movement disorders, were diagnosed with leukoencephalopathy with calcifications and cysts (MIM: 616663) due to compound heterozygous pathogenic variants (n.74G>A; n.*10G>A and n.3C>T; n.75A>G) in small nucleolar RNA SNORD118 (box C/D snoRNA U8), required for ribosomal biogenesis and function.
Treatment with anti-VEGF antibody bevacizumab was shown to have beneficial effects on extrapyramidal symptoms and cyst size on brain MRI [21]. We started VEGF inhibition in patient 4 which led to a significant cyst size reduction, though long-term clinical effects remain to be determined.

Patient 9 was referred to UD-PrOZA because of unexplained developmental delay, tremor, dyspraxia, and hypergonadotropic hypogonadism. After a diagnostic odyssey of 18 years including serial targeted genetic testing, she was diagnosed with galactosemia due to a homozygous pathogenic variant (p.Gln188Arg) in GALT (Galactose-1-Phosphate Uridydyltransferase) (MIM: 230400). Restriction of galactose intake and replacement of milk products by lactose-free formulas was advised with favorable effect on our patient’s symptoms and performance level.
Patient 6, a young female with a history of androgenetic alopecia presenting with pellagra-like dermatitis secondary to sun exposure, was diagnosed with Hartnup disease (MIM: 234500), caused by compound heterozygous variants in SLC6A19 (p.Asp173Asn, p.Glu519Gly). Elevated excretion of neutral amino acids in urine confirmed the pathogenicity of these variants. A protein rich diet, avoidance of excessive exposure to sunlight and the intake of nicotinamide supplements was started.

Patient 10, a young male with a history of developmental delay and a diagnosis of autism spectrum disorder, was referred to UD-PrOZA because of subacute bilateral vision loss due to bilateral optic neuritis. Biochemical analysis showed severely decreased biotinidase enzyme activity (< 0.01 nmol/min/mL). Genetic testing of the BTD gene revealed compound heterozygosity for pathogenic variants (p.Gly36Ser, p.Cys425Arg), thereby confirming the diagnosis of biotinidase deficiency (MIM: 253260). After initiation of biotin supplements, significant improvement of vision and motor skills was seen. A more detailed description of this case has been published recently [22].

Patients 23 and 51 are discussed in other sections.

**Expanding the phenotypic spectrum**

Inherent to rare diseases is the incomplete ascertainment of their phenotypic spectrum due to the small size of published patient cohorts. In 4 cases (8%) (Additional file 2: Table S3) we were able to expand the phenotypic spectrum of the disease.

Patient 8 is the third child of healthy non-consanguineous parents, with a medical history of recurrent intracerebral hemorrhages with diffuse microbleeds and periventricular and pontine hyperintensities on brain MRI, was referred to UD-PrOZA by his general practitioner (Fig. 1A–D, Additional file 2: Table S3). Additionally, the patient suffered from recurrent paralytic ileus and hyperpigmented skin lesions. WES revealed the presence of a homozygous missense variant in the SGO1 gene (p.Lys23Glu), a known pathogenic founder mutation associated with autosomal recessive chronic atrial and intestinal dysrhythmia (CAID syndrome, MIM: 616201) [23]. SGO1 encodes shugoshin-like 1 protein, which has a crucial function in the mitotic cell cycle by providing a link between the sister centromere cohesion complex and microtubules at kinetochores. Patients typically present with sick sinus syndrome requiring cardiac pacemakers and intestinal myogenic and neurogenic pseudo-obstruction. Recently, a novel association was reported between CAID syndrome and cerebral small vessel disease [24]. It was hypothesized that this cerebral vascular phenotype is a consequence of upregulated TGF-β signaling leading to vessel wall fibrosis and premature senescence of cerebellar arterioles due to mitotic dysregulation [23, 24]. Our patient is the third CAID patient in the literature in which cerebral small vessel disease is reported. This novel association might have important consequences, since a majority of the patients with cardiac arrhythmias is treated with anticoagulation therapy, increasing the risk of cerebral hemorrhages.

A young female of Tunisian origin (patient 18), born from consanguineous parents (Fig. 1H), was referred because of disabling chronic migraine and abnomalities on brain MRI including widened Virchow-Robin spaces and periventricular white matter hyperintensities (Fig. 1G). Additionally, she has a torticollis due to a congenital unilateral fusion of cervical vertebrae C1-C6 (Fig. 1E, F). WES identified a homozygous splice region variant in RIPPLY2 (c.240-4T>G) (Additional file 2: Table S3), a known founder mutation associated with spondylocostal dysostosis 6 (MIM: 616566) [25]. Although a clear effect on splicing in postnatal tissue has never been proven due to the embryonic expression of this gene, we classified this gene as likely pathogenic since in the literature, seven patients have been reported presenting with congenital posterior cervical spine malformations in which this splice region mutation was identified in homozygous or compound heterozygous state [24]. In only one patient a Klippel-Feil syndrome (fusion of the cervical vertebrae) was reported, all other patients presented with agenesis of the posterior vertebral elements. Whether this variant could also be explanatory for the findings on brain MRI, remains elusive and the possibility of a second yet unidentified molecular cause has to be taken into account.

Patient 48 was referred for genetic testing because of a dilated cardiomyopathy. Additionally, he suffers from chronic back pain for which he is treated with a neurostimulator after failed back surgery. He complained of proximal muscle weakness and myalgia, predominantly of the upper limbs. WES revealed compound heterozygous pathogenic variants in SELENON (p.Val447Met, c.997_1000del), associated with rigid spine muscular dystrophy 1 (MIM: 602771). Selenoprotein N, an endoplasmic reticulum glycoprotein, plays a key role in redox-based calcium homeostasis and protects the cell against oxidative stress. In the literature, one patient with pathogenic bi-allelic SELENON variants and dilated cardiomyopathy was reported [26]. Other reported SELENON-related cardiac abnormalities include cor pulmonale and valvular disease. As such, we establish dilated cardiomyopathy as a feature being part of the rigid spine muscular dystrophy 1 phenotypic spectrum.

Patient 21 is discussed elsewhere.
Use of model organisms
Small model organisms (Drosophila melanogaster/ Danio rerio) provide us with unique in vivo readouts helping us to understand the biological relevance of variants of unknown significance identified through NGS techniques.

Patient 21 was referred because of small stature, dysmorphic features, fused cervical vertebrae, dilated cardiomyopathy, conductive hearing loss and joint hyperlaxity (Fig. 2A). WES identified a previously unreported de novo heterozygous missense variant in the MAP3K7 gene (p.Gly191Arg), located in the conserved catalytic kinase domain of the enzyme (Fig. 2B, Additional file 2: Table S3). MAP3K7 encodes the transforming growth factor-β-activated kinase 1 (TAK1) which plays an important role in the cascade of cellular responses evoked by changes in the environment. Pathogenic variants in this gene cause autosomal dominant cardio-spondylocarpofacial syndrome (CSCFS, MIM: 157800) and frontometaphyseal dysplasia 2 (FMD2, MIM: 61737), depending on the loss-of-function (LoF) or gain-of-function (GoF) nature of the causal variant. The p.Gly191Arg variant is not present in gnomAD, has deleterious in silico predictions and replaces a highly conserved glycine residue for an arginine residue, an amino acid with different physicochemical properties (Fig. 2B). In order to investigate the LoF or GoF mechanism of this novel variant we used Drosophila to assess kinase activity. It has been shown that hyperfunction of the TAK1 kinase in the fly eye, results in a rough eye phenotype [27]. We replicated these findings and observed that eye-specific overexpression of wild-type fly and human TAK1 resulted in a severe eye phenotype, even causing pupal lethality (Fig. 2C). Next, we exploited these findings to assess the effect of known variants on the kinase activity [28, 29]. Overexpression of known pathogenic LoF variants (c.148_150delGTT, p.Gly110Cys), completely reversed the phenotype, whereas overexpression of known GoF variants (p.Glu70Gln, p.Gly168Arg) preserving kinase activity mimic the wild-type phenotype. It has been shown that patients heterozygous for the p.Gly168Arg variant present with a less severe FMD phenotype, which is reflected in a less severe eye phenotype or even no phenotype when overexpressing the fly and human TAK1 with this variant [30]. Overexpression of fly and human TAK1 with our novel variant (p.Gly191Arg) resulted in seemingly healthy flies with normal eyes and normal life spans, as such establishing a LoF nature of this missense variant. This case illustrates the use of small model organisms for quick variant modeling in diagnostics of rare disease. Furthermore, this case expands the phenotypic spectrum of the CSCF syndrome, since cardiomyopathy is a feature which has not been associated with this syndrome before.

Identification of novel disease genes
UD-PrOZA contributed to the discovery of three new disease genes (Table S3: ID 3, 23, 51) by performing hypothesis-free NGS testing and using the GeneMatcher [6] platform to get in touch with other researchers that identified variants in the same candidate genes.

A male patient (patient 3) with severe intellectual disability, epilepsy, absence of speech, ataxia, choreo-athetosis and generalized dystonia was referred by the neurologist for genetic testing. The first signs of motor regression started at the age of 5 years and worsened over time, resulting in wheelchair dependence since the age of 28. Trio-WES analysis detected a de novo heterozygous nonsense variant (p.Gln126Ter) in the IRF2BP1 gene (Interferon regulatory factor 2 binding protein-like), which encodes a member of the IRF2BP family of transcriptional regulators (Table S3). The gene had not been associated with a phenotype in humans. The present case is part of the initial study describing LoF variants in IRF2BP1 as the cause of the novel disorder ‘Neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures’ (MIM: 618088) [31].

Patient 23, a female patient born from consanguineous Turkish parents, was referred to UD-PrOZA for genetic testing for an unexplained partial lipodystrophy phenotype. She and two female siblings presented with lipatrophy of the limbs and trunk, dyslipidemia, insulin resistant diabetes and hepatosteatosis. Through WES and WGS, we identified a homozygous 5092 bp
deletion encompassing exon 2 of the PLAT3 gene within a shared homozygous region. This gene encodes an adipocyte specific phospholipid modifying enzyme which we showed to serve as an important regulator of PPAR-γ activity, the master regulator of adipocyte differentiation and function. The detailed study in which we
establish PLAAT3 deficiency as a novel cause for autosomal recessive familial partial lipodystrophy is described elsewhere (https://doi.org/10.1101/2021.04.15.439941v1. article-metrics).

Patient 51, a female patient born from consanguineous parents, was referred because of unexplained subacute anhedonia, hallucinations, motor problems, dysarthria, insomnia and diffuse leukoencephalopathy on brain MRI. WES identified a homozygous nonsense variant (p.Arg183Ter) in the ACMSD gene, encoding the enzyme aminocarboxymuconate-semialdehyde-decarboxylase, involved in the catalytic breakdown of tryptophan into NAD⁺. The enzyme is located at a key branch-point of the pathway, limiting the production of the neurotoxin quinolinic acid, which has excitotoxic and pro-inflammatory properties. SNPs and heterozygous rare variants in ACMSD have been associated with neurodegenerative diseases such as Parkinson’s disease [32, 33]. Moreover, this enzyme was appointed as a potential therapeutic target for neurodegenerative diseases. The homozygous nonsense variant identified in this patient is predicted to induce nonsense mediated decay and in silico predictions suggest pathogenicity. In population database gnomAD no homozygous LoF alleles have been reported. Additionally, using GeneMatcher [6] we identified a second pediatric patient with a severe neurological phenotype and a homozygous LoF variant in ACMSD. The variants identified in the two patients are predicted to induce nonsense mediated decay and as such completely abrogate the aminocarboxymuconate-semialdehyde-decarboxylase enzyme activity. Further investigations and functional analyses are currently ongoing to elaborate on this novel disease gene. We hypothesize that a diet poor in tryptophan might have beneficial effects on the neurological features seen in both patients.

Discussion
In this study we present UD-PrOZA, a novel multidisciplinary diagnostic platform, established at the Ghent University Hospital in Belgium in May 2015. UD-PrOZA aims to facilitate the diagnostic process for adult patients with suspected rare diseases by integrating a multidisciplinary clinical evaluation, state-of-the-art genomic technology and data sharing. Compared to other initiatives, UD-PrOZA is unique in terms of both modus operandi as well as the main field of interest. Unlike other initiatives, UD-PrOZA is a monocentric platform and accepts only referrals from other physicians, which has proven an efficient first filter before approval of the application. Comparable rare diseases initiatives predominantly focus on pediatric unsolved cases, whereas UD-PrOZA is mainly involved in diagnosing adult-onset rare diseases and adult patients with longstanding unexplained disease, that often already started at a young age. An overview of other rare disease programs and initiatives is provided in Table 3. With diagnostic rates between 35 and 67% [14–19], other initiatives outscore UD-PrOZA which was able to diagnose 18% of all accepted cases. This discordance can be most likely attributed to the age difference of the patient cohorts since other initiatives focus on pediatric cases often presenting with severe neurodevelopmental phenotypes and/or congenital malformations [14, 18]. The a priori chance of identifying an underlying molecular cause is higher in children, presenting with more severe and typical phenotypes, as opposed to adults which often present with an atypical or attenuated phenotype [9, 34]. Nevertheless, with a diagnostic rate of 18% we show that advanced age should not be a counter-argument to initiate exome-based genetic testing. We showed that the presence of objective disease signs is an important criterium to evaluate the likelihood of an underlying rare disease and a prerequisite to initiate genetic testing. Currently, exome-based gene panel testing is done in our center in a diagnostic setting in adults. Analysis of the entire Mendeliome however, is limited to prenatal, neonatal and research settings.

The mean time interval between symptom-onset and diagnosis was 19 years. This diagnostic delay is associated with numerous doctor visits and investigations,
putting an enormous burden on health care budgets. More importantly, these patients remain in limbo concerning prognosis and the recurrence risk for family members, inducing high levels of anxiety. This striking diagnostic delay emphasizes the need for alternative approaches to diagnose rare diseases.

Inherent to the early implementation of WES-based diagnostic testing is the identification of incidental findings. In 7% of the patients in whom WES was performed, actionable incidental findings were reported, which is in accordance with the frequency reported in the literature ranging from 2.5 to 12% [35–37].

This study and the proposed diagnostic platform have several limitations. The restriction of referral by healthcare providers only, can be a limiting factor for patients to be evaluated by UD-PrOZA. However, it has been shown in previous studies that a large proportion of patients who directly contact centers for rare undiagnosed diseases, presented with subjective complaints (pain symptoms, fatigue, irritable bowel syndrome) and were never evaluated at the tertiary level [38]. Furthermore, we did not evaluate the cost-effectiveness of our diagnostic approach in which exome-based genetic testing is initiated in an early phase of the diagnostic process. Although the implementation of NGS genetic testing for suspected monogenic disorders has shown to be cost-effective in children, comparable data in adults is lacking [9, 10, 39, 40].

The diagnostic yield of 22% after genetic testing is probably an underestimation, taken into account the frequent identification of class 3 variants, potentially associated with the patient phenotype. Further functional analyses and/or data sharing efforts are currently undertaken to address the potential causality of these variants. A diagnostic yield of 22% implies that in the majority of the cases in which a monogenic disease is suspected, we could not identify the underlying molecular cause. There are several potential reasons why we were not able to identify the causal mutation. First, there might not be a monogenic cause underlying the phenotype of the patient. In some cases, Mendelian disorders can be difficult to distinguish from multifactorial diseases (e.g., stroke, Parkinson’s disease, autoimmune syndromes, etc.). Second, pathogenic

| Name                                                      | Referred patients | Monocentric/ multicentric | Accepted patients* | % of patients < 18y | Diagnostic rate | Phenotypes                              | Reference                        |
|-----------------------------------------------------------|-------------------|----------------------------|---------------------|---------------------|-----------------|-----------------------------------------|-----------------------------------|
| Initiative on Rare and Undiagnosed Disease in Japan (IRUD) | 5359              | Multicentric               | 4205                | NA                  | 42.9%           | Diverse                                 | Takahashi et al. [15]             |
| Undiagnosed Disease Network (UDN)                         | 1519              | Multicentric               | 601                 | 57%                 | 35%             | Diverse                                 | Splinter et al. [14]              |
| Program for undiagnosed rare diseases (UD-PrOZA)         | 692               | Monocentric                | 329                 | 6.7%                | 18%             | Diverse                                 | This study                       |
| Singapore Undiagnosed Disease Program                     | NA                | Multicentric               | 196                 | 90%                 | 37.2%           | Diverse                                 | Bhatia et al. [16]                |
| The Korean undiagnosed diseases program (KUDP)            | NA                | Multicentric               | 72                  | 94.8%               | 38.9%           | Diverse                                 | Kim et al. [17]                  |
| Spain UDP                                                 | NA                | Multicentric               | 30                  | 74.1%               | 6.7%            | Diverse                                 | López-Martín et al. [18]          |
| The Italian Undiagnosed Rare Diseases Network (IURDN)    | 110               | Multicentric               | 13                  | 31% (92% onset < 18y) | 53.8%           | Diverse                                 | Salvatore et al. [19]             |
| Undiagnosed Diseases Program – Western Australia (UDP-WA) | NA                | Multicentric               | NA                  | NA                  | NA              | NA                                      | Baynam et al. [46]                |
| National Network to Collaborate on Diagnosis and Treatment of Rare Diseases China | NA | Multicentric | NA | NA | NA | NA | Ren et al. [47] |

NA: not available
* In which genotyping and phenotyping were finished
variants in genes which have not yet been established as disease genes (OMIM) might be underlying the phenotype emphasizing the importance of periodic reanalysis of exome data [41]. Third, the technique of short read whole exome sequencing has its shortcomings and is not suited to detect repeat expansions or variation in non-coding sequences. Additionally, coding variants might be missed due to insufficient coverage or low-grade mosaicism.

As a part of its future perspectives, UD-PrOZA is now implementing WGS and RNA sequencing to identify pathogenic variants in non-coding sequences. In a UDN patient cohort, 24% of all genetic diagnoses were based on WGS technology [14]. We predict that performing WGS in unexplained cases will significantly increase the diagnostic rate since it was shown in the literature that WGS has a higher diagnostic yield compared to WES across a variety of clinical indications [42]. In studies comparing WGS with conventional genetic testing (i.e. gene panel testing) and exome sequencing, a diagnostic increase was seen between 14.5 and 17% in favor of WGS [43, 44]. The missed diagnoses included structural and non-exonic sequence variants not detected with WES, but also variants previously missed due to technical problems such as incomplete coverage. Interestingly, it was shown that 30% of the positive cases identified by WGS in a WES-negative cohort, could also have been identified by reanalyzing the WES data resulting in an overestimation of the clinical utility of WGS [45]. That is why UD-PrOZA will systematically reanalyze the existing WES and WGS data as knowledge on rare diseases quickly expands, including the continuous discovery of new diseases, genes and pathogenic variants [41]. Lastly, UD-PrOZA is making an effort to facilitate the online referral platform and to integrate artificial intelligence to improve case selection and diagnostic yield.

Conclusion
UD-PrOZA offers an innovative platform to diagnose rare diseases in adults. With a total diagnostic rate of 18%, this multidisciplinary approach, combined with early implementation of exome-based genetic testing and close collaboration with research facilities has proven to be an efficient strategy to diagnose previously unrecognized rare diseases.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02365-y.

Acknowledgements
The authors would like to thank the patients who participated in this study and the clinicians who referred patients to the rare disease program. DH would like to thank Mrs. Sabine van Sprang and the whole team at the Academia Belgica, Center for History, Arts and Sciences in Rome, Italy (https://www.academiabelgica.it), for supporting the writing of this manuscript. Authors of this publication are members of the European Reference Network for Rare Neurological Diseases (ERN-RND) and of the Solve-RD Consortium. For more information about the ERNs and the EU health strategy visit http://ec.europa.eu/health/ern. For more information about Solve-RD visit https://solve-rd.eu.

UD-PrOZA collaborators
Jan De Bleecker, Patrick Santens, Paul Boon, Guy Laureys, Tessa Kerre.

Web resources
http://solve-rd.eu, https://gnomad.broadinstitute.org, https://ec.europa.eu/health/sites/health/files/rare_diseases/docs/2014_rarediseases_implementationreport_en.pdf, https://omim.org

Author contributions
The data published in this study are generated by the UD-PrOZA group. NS and DH were involved in the conceptualization, methodology, resource provision, formal analysis, investigation, data curation, writing of the original draft and visualization. DH, SC, WT, BD and BP were involved in conceptualization, validation, investigation, resource generation, project administration, supervision, reviewing and editing of the manuscript. ED acquired funding. RVC, BC, FH, SS, AV and PV were involved in the investigation process, provision of resources and revision of the manuscript. PIC, ED, JG, LN, WS and HV were involved in the genetic diagnostic analyses, computing resources, analysis tools and software. EB and PLB were involved in the investigation process, by generating the MAP3K7 Drosophila model. All authors read and approved the final manuscript.

Funding
The Program for Undiagnosed Diseases (UD-PrOZA) is supported by the Spearhead Research Policy Program and the Fund for Innovation from the Ghent University Hospital. BD is supported by an Odysseus type 1 Grant of the Research Foundation Flanders (3GOH8318) and a starting grant from Ghent University Special Research Fund (01N10319). BC is a senior clinical investigator of the Research Foundation Flanders. NS is a beneficiary of FWO PhD fellowship.

Data availability statement
The data that support the findings of this study are available on request from the corresponding author.

Declarations
Ethics approval statement
The study was approved by the Ethics Committee of the University Hospital of Ghent (EC: 2019/1430).

Consent for publication
This study contains anonymized genotypic and phenotypic patient data. No direct patient identifiers have been provided in this manuscript. All patients in which WES was initiated, including the patients described in the case reports, signed informed consents for publication of personal data.

Competing interests
The authors declare no competing interests.

Author details
1Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.
2Department of Biomolecular Medicine, Faculty of Medicine and Health
Sciences, Ghent University, Ghent, Belgium. 1Department of Neurology, Ghent University Hospital, Ghent, Belgium. 2Department of Nephrology, Jan Yperman Hospital, Leper, Belgium. 3Department of General Internal Medicine, Ghent University Hospital, Ghent, Belgium. 4Department of Pediatrics, Division of Pediatric Neurology and Metabolic Diseases, Ghent University Hospital, Ghent, Belgium. 5Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands. 6Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium. 7Primary Immunodeficiency Research Lab, Center for Primary Immunodeficiency Ghent, Jeffrey Modell Diagnosis and Research Center, Ghent University Hospital, Ghent, Belgium.

Received: 17 December 2021 Accepted: 13 May 2022
Published online: 23 May 2022

References

1. Julkowska D, Austin CP, Cutillo CM, Gancberg D, Hager C, Halftermeyer J, et al. The importance of international collaboration for rare diseases research: a European perspective. Gene Ther. 2017;24(9):562–71.

2. Fernandez-Marmiesse A, Gouveia S,Couce ML. NGS technologies as a turning point in rare disease research. Diagnosis Treat Curr Med Chem. 2018;25(3):404–22.

3. Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare diseases research 2010–2016: an IRD IRC perspective. Clin Transl Sci. 2018;11(1):11–20.

4. Nuengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.

5. Rath A, Salamon V, Peixoto S, Hivert V, Laville M, Segrestin B, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18(1):556.

6. Sobreira N, Schiettecatte F, Vaille D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36(10):928–30.

7. Wanger MF, Yamamoto S, Chao HT, Posey JE, Westerfield M, Postlethwait J, et al. Model organisms facilitate rare disease diagnosis and therapeutic research. Genetics. 2017;207(1):9–27.

8. Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am J Hum Genet. 2017;100(5):695–705.

9. Shick S, Milton C, Uleyk E, Peclihvanoglu P, Bombard Y. The clinical utility of exome and genome sequencing across clinical indications: a systematic review. Hum Genet. 2021;140(10):1403–16.

10. Srivastava S, love-Nichols JA, Dies KA, Ledbetter DH, Martin CL, Chung WK, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019;21(11):2413–21.

11. Matilla-Dueñas A, Corral-Juan M, Rodriguez-Palmero Seuma A, Vilas D, Ispierto L, Morais S, et al. Rare neurodegenerative diseases: clinical and genetic update. Adv Exp Med Biol. 2017;1031:443–96.

12. Sobreira NLM, Arachchi H, Buske DJ, Chong JX, Hutton B, Foreman J, et al. Matchmaker exchange: Curr Protoc Hum Genet. 2017;95:9.3.1–9.15.

13. Brownstein CA, Holm IA, Ramoni R, Goldstein DB. Data sharing in the International cooperation to enable the diagnosis of all rare genetic diseases. Gene. 2017;609(1):392–406.

14. Nehme A, Gioia LC, Jacquin G, Poppe AV, Letourneau-Guillon L, Odière C. Chronic ataxial intestinal dysrhythmia syndrome is associated with cerebral small vessel disease and predominantly cerebellar microbleeds. Can J Neurol Sci. 2020;47(4):566–8.

15. Serey-Gaut M, Scala M, Reverende BS, Rusaud L, Cabrol C, Musacchia F, et al. Congenital posterior cerebral spine malformation due to bial- lelic c.2404T>G (RP11Y2 variant: a discrete entity. Am J Med Genet A. 2020;182(6):1466–72.

16. Villar-Quiles RN, von der Hagen M, Metyà C, Gonzalez V, Donkervoort S, Berti E, et al. The clinical, histologic, and genotypic spectrum of SEPN1-related myopathy: a case series. Neurology. 2020;95(11):e1512–7.

17. Shin JH, Min SH, Kim SJ, Kim Y, Park J, Lee HK, et al. TAK1 regulates autophagic cell death by suppressing the phosphorylation of p70 S6 kinase 1. Sci Rep. 2013;3:1356.

18. Le Goff C, Rogers C, Le Goff P, Ginto G, Bonnet D, Chrabieh M, et al. Heterozygous mutations in MAP3K7, encoding TGF-β-activated kinase 1, cause cardiopulmonary fibrocanciofacial syndrome. Am J Hum Genet. 2016;99(2):407–13.

19. Morlino S, Castori M, Dordoni C, Cinquina V, Santoro G, Grammatico P, et al. A novel MAP3K7 splice mutation causes cardiopulmonary fibrocanciofacial syndrome with features of hereditary connective tissue disease. Eur J Hum Genet. 2018;26(4):582–6.

20. Wade EM, Daniel PB, Jenkins ZA, McInerney-Leo A, Leo P, Morgan T, et al. Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontotemporal dysplasia. Am J Hum Genet. 2016;99(2):392–406.

21. Marconcigli P, Shashi V, Spillmann RC, Stong N, Rosenfeld JA, Koenig MK, et al. IRF2BPL is associated with neurological phenotypes. Am J Hum Genet. 2018;103(2):245–60.

22. Thirtamara-Rajamani K, Li P, Escobar Galvis ML, Labrie V, Brundin P, et al. Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontotemporal dysplasia. Am J Hum Genet. 2018;103(2):245–60.

23. Chetaille P, Preuss C, Burkhard S, Côté JM, Houde C, Castilloux J, et al. Meta-analysis and multidisciplinary consensus statement: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.

24. Fay AJ, King AA, Shimony JS, Crow YJ, Brunstrom-Hernandez JE. Treatment of leukoencephalopathy with calcifications and cysts with bevacizumab. Pediatr Neurol. 2017;71:56–9.

25. Van Iseghem V, Sprengers M, De Zaeytijd J, Sindic CJM, Willekens B, Dermaut B, et al. Biotinidase deficiency: a treatable cause of opticociphalic syndrome in young adults(4). Mult Scler Relat Disord. 2019;32:64–9.

26. Chetelat P, Preuss C, Burkhard S, Côté JM, Houde C, Castilloux J, et al. Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut. Nat Genet. 2014;46(8):1245–9.

27. Shin JH, Min SH, Kim SJ, Kim Y, Park J, Lee HK, et al. TAK1 regulates autophagic cell death by suppressing the phosphorylation of p70 S6 kinase 1. Sci Rep. 2013;3:1356.

28. Le Goff C, Rogers C, Le Goff P, Ginto G, Bonnet D, Chrabieh M, et al. Heterozygous mutations in MAP3K7, encoding TGF-β-activated kinase 1, cause cardiopulmonary fibrocanciofacial syndrome. Am J Hum Genet. 2016;99(2):407–13.

29. Morlino S, Castori M, Dordoni C, Cinquina V, Santoro G, Grammatico P, et al. A novel MAP3K7 splice mutation causes cardiopulmonary fibrocanciofacial syndrome with features of hereditary connective tissue disease. Eur J Hum Genet. 2018;26(4):582–60.

30. Wade EM, Daniel PB, Jenkins ZA, McInerney-Leo A, Leo P, Morgan T, et al. Mutations in MAP3K7 that alter the activity of the TAK1 signaling complex cause frontotemporal dysplasia. Am J Hum Genet. 2018;99(2):392–406.

31. Varma C, Bermejo-Sánchez E, Alonso J, Posada M. SpainUDP: The Spanish Undiagnosed Rare Diseases Program. Int J Environ Res Public Health. 2018;15(8):1746.
40. Stark Z, Tan TY, Chong B, Brett GR, Yap P, Walsh M, et al. A prospective evaluation of whole-exome sequencing as a first-tier molecular test in infants with suspected monogenic disorders. Genet Med. 2016;18(11):1090–6.
41. Liu P, Meng L, Normand EA, Xia F, Song X, Ghazi A, et al. Reanalysis of clinical exome sequencing data. N Engl J Med. 2019;380(25):2478–80.
42. Mattick JS, Dinger M, Schonrock N, Cowley M. Whole genome sequencing provides better diagnostic yield and future value than whole exome sequencing. Med J Aust. 2018;209(5):197–9.
43. Bertoli-Avella AM, Beetz C, Ameiziane N, Rocha ME, Guatibonza P, Pereira C, et al. Successful application of genome sequencing in a diagnostic setting: 1007 index cases from a clinically heterogeneous cohort. Eur J Hum Genet. 2021;29(1):141–53.
44. Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med. 2018;20(4):435–43.
45. Alfares A, Aloraini T, Subaie LA, Alisra A, Qudsi AA, Alahmad A, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. Genet Med. 2018;20(11):1328–33.
46. Baynam G, Brole S, Bauskis A, Pachter N, McKenzie F, Townshend S, et al. Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet J Rare Dis. 2017;12(1):83.
47. Ren Q, Wang J. Network established to collaborate on diagnosis and treatment of rare diseases in China: A strategic alliance backed by tiered healthcare is the key to the future. Intractable Rare Dis Res. 2019;8(1):78–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.